1-substituted-3-pyrrolidine derivatives as muscarinic...

Details 1-substituted-3-pyrrolidine derivatives as muscarinic... 1-substituted-3-pyrrolidine derivatives as muscarinic...

2002-12-23

2008-12-16

McKane, Joseph (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S424000, C548S541000, C548S542000, C548S525000, C548S526000

Reexamination Certificate

active

07465751

ABSTRACT:
This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention. pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

REFERENCES:
patent: 2956062 (1960-10-01), Lunsford
patent: 3091570 (1963-05-01), Biel
patent: 3176019 (1965-03-01), Campbell et al.
patent: 5281601 (1994-01-01), Cross et al.
patent: 5948792 (1999-09-01), Tsuchiya et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6174900 (2001-01-01), Okada et al.
patent: 0 012 071 (1980-06-01), None
patent: 0 325 571 (1989-07-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 801 067 (1997-10-01), None
patent: 0 823 423 (1998-02-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: 940540 (1963-10-01), None
patent: 92921/1994 (1994-04-01), None
patent: 135958/1994 (1994-05-01), None
patent: WO 91/09013 (1991-06-01), None
patent: WO 93/16048 (1993-08-01), None
patent: WO 96/33973 (1996-10-01), None
patent: WO 97/45414 (1997-12-01), None
patent: WO 98/00016 (1998-01-01), None
patent: WO 98/00109 (1998-01-01), None
patent: WO 98/00132 (1998-01-01), None
patent: WO 98/00133 (1998-01-01), None
patent: WO 98/05641 (1998-02-01), None
patent: WO 98/21183 (1998-05-01), None
patent: WO 98/29402 (1998-07-01), None
patent: WO 02/04402 (2002-01-01), None
Bundgaard, Design of prodrugs, 1985, Elsevier, p. 1-9.
Maureen Rouhi, Chemical & Engineering News, Feb. 24, 2004, p. 32-35.
Haleblian et al. Journal of Pharmaceutical Science, Aug. 1969, vol. 58, No. 8, p. 911-912.
Koppanyi, 88:130844, 1974.
Kubo et al., “Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor”,Nature, 323(2):411-416 (1986).
Bonner et al., “Identification of a Family of Muscarinic Acetylcholine Receptor Genes”,Science, 237:527-531 (1987).
Eglen et al., “Muscarinic Receptor Ligands and Their Theraputic Potential”,Current Opinions in Chemical Biology, 3(4):426-432 (1999) XP000972296, ISSN: 1367-5931.
Eglen et al., “Theraputic opportunities from muscarinic receptor research”,Trends in Pharmacological Sciences, 22(8):409-414 (2001).
Felder et al., “Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System”,Journal of Medicinal Chemistry, 43(23):4333-4353 (2000).
Broadley and Kelly, “Muscarinic Receptor Agonists and Antagonists”,Molecules, 6:142-193 (2001).
Birdsall et al., “Muscarinic receptors: it's a knockout”,Trends in Pharmacological Sciences, 22(5):215-219 (2001).
de Groat and Yoshimura, “Pharmacology of the Lower Urinary Tract”,Annual Review of Pharmacology and Toxicology, 41:691-721 (2001).
Steers, “The future direction of neuro-urology drug research”,Current Opinion in CPNS Investigational Drugs, 2(3):268-282, (2000).
Chapple, “Muscarinic receptor antagonists in the treatment of overactive bladder”,Urology, 55(Suppl. 5A):33-46 (2000).
Steers, Barrot, Wein, “Voiding dysfunction: diagnosis classification and management”, In:Adult and Pediatric Urology, ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996).
Sagara et al., “Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3Antagonist Discriminating against the Other Receptor Subtypes”,Journal of Medicinal Chemistry, 45:984-987 (2002) XP002238502, ISSN: 0022-2623.
Moriya et al., “Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland”,Life Sciences, 64(25):2351-2358 (1999).
Cheng and Prusoff, “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction”,Biochemical Pharmacology, 22:3099-3108 (1973).
Franko et al., “Derivatives of 3-Pyrrolidinols-III. The Chemistry, Pharmacology, and Toxicology of some N-Substituted-3-Pyrrolidyl alpha-Substituted Phenylacetates”,Journal of Medicinal and Pharmaceutical Chemistry, 2:523-540 (1960).
Biel et al., “Central Stimulants. II. Cholinergic Blocking Agents”,Journal of Organic Chemistry, American Chemical Society, 26, 4096-4103 (1961).
Taniguchi et al., “Agents for the Treatment of Overactive Detrusor. VI. Synthesis and Pharmacological Properties of Acetamide Derivatives Bearing Cyclic Amines in N-Substituents”,Chemical and Pharmaceutical Bulletin, 42(1):74-84 (1994).
O'Neill et al., “Biochemical effects of psychotomimetic anticholinergic drugs”,Advances in Biochemical Psychopharmacology, 6:203-218 (1972).

Affiliated with

Also associated with

Rating

1-substituted-3-pyrrolidine derivatives as muscarinic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 1-substituted-3-pyrrolidine derivatives as muscarinic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-substituted-3-pyrrolidine derivatives as muscarinic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4024927